| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10efc646a4dd605c2f09c493718f5b81 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 |
| filingDate |
2008-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d881101392f26c13e7772275c918164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1998c930440026582f42caa6b4022d51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_685910a1e4ff898d1df1a87bab09fec4 |
| publicationDate |
2010-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2383345-C1 |
| titleOfInvention |
Method of treating patients with bronchial asthma |
| abstract |
FIELD: medicine. n SUBSTANCE: invention can be applied for treatment of patients with bronchial asthma of medium-severe or severe clinical course in phase of exacerbation with high risk of sinus tachycardia development. If high risk of sinus tachycardia development is determined, ivabradine is introduced in standard complex of treatment, which includes beta2-agonists. Medicine is used during all exacerbation period in daily doze 10-14 mg. n EFFECT: method allows to increase treatment safety and efficiency of correcting side effect of high doses of beta2-agonists. n 2 cl, 10 tbl, 2 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2533284-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017173458-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2676333-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2703568-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11273162-B2 |
| priorityDate |
2008-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |